Treatment of narcolepsy

Expert Review of Neurotherapeutics

Volumn 9, Issue 6, 2009, Pages 897-910

  Didato, Giuseppe ^a,b   Nobili, Lino ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cataplexy; Modafinil; Narcolepsy; Sodium oxybate; Treatment

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BUSPIRONE; CAFFEINE; CALCIUM ANTAGONIST; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CYCLOSPORIN; DEXAMPHETAMINE; ETHINYLESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAZINDOL; METHYLPHENIDATE; MIDAZOLAM; MODAFINIL; ORAL CONTRACEPTIVE AGENT; OXYBATE SODIUM; PEMOLINE; PHENYTOIN; PROPRANOLOL; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; REBOXETINE; SELEGILINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AGGRESSIVENESS; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANOREXIA; ANXIETY; AWARENESS; BEHAVIOR THERAPY; CATALEPSY; CATAPLEXY; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; EJACULATION DISORDER; EUPHORIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPNAGOGIC HALLUCINATION; HYPOCRETIN DEFICIENCY; IMMUNOTHERAPY; IMPOTENCE; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIBIDO; LIVER TOXICITY; MICTURITION DISORDER; MOOD CHANGE; MORNING DOSAGE; MUSCLE DISEASE; MUSCLE JERK; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROBIOLOGY; NIGHT SLEEP; NOCTURNAL ENURESIS; NOCTURNAL SLEEP DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PREVALENCE; PROTEIN DEFICIENCY; PSYCHOSIS; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; SUICIDAL BEHAVIOR; SWEATING; SYMPTOM; TACHYCARDIA; TIRENESS; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NARCOLEPSY; SODIUM OXYBATE; SYMPATHOMIMETICS;

EID: 67649947206     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.29     Document Type: Review

References (96)

1. Westphal C. Eigentümliche mit Einschlafen verbundene Anfälle. Arch. Psychiatr. Nervenkr. 7, 631-635 (1877).
2. Gelineau J. De la narcolepsie. Gaz. Hôp Paris 55, 635-637 (1880).
3. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 8, 373-399 (2007). •• Comprehensive review of the neurobiological and pathophysiological mechanisms of narcolepsy. (Pubitemid 46722263)
4. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 369, 499-511 (2007). •• Comprehensive review on the clinical aspects and therapeutic management of narcolepsy. (Pubitemid 46209316)
5. Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city. Sleep Res. 8, 191 (1979).
6. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 10, 608-609 (1987).
7. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med. 8, 427-440 (2007). •• Comprehensive review on the therapeutic management of narcolepsy. (Pubitemid 46706356)
8. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 58, 1826-1833 (2002). (Pubitemid 34663586)
9. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 25, 197-202 (2002). (Pubitemid 34193581)
10. Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med. 5(1), 37-41 (2004). (Pubitemid 38145710)
11. Dauvilliers Y, Montplaisir J, Molinari N et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57, 2029-2033 (2001). (Pubitemid 33126870)
12. Orellana C, Villemin E, Tafti M, Carlander B, Besset A, Billiard M. Life events in the year preceding the onset of narcolepsy. Sleep 17(Suppl. 8), S50-S53 (1994).
13. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy. Lancet 2(8676), 1376-1379 (1989). (Pubitemid 20002976)
14. Billiard M, Pasquie-Magnetto V, Heckman M, Carlander B, Besset A, Billiard M. Family studies in narcolepsy. Sleep 17(Suppl. 8), S54-S59 (1994).
15. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual (2nd Edition). American Academy of Sleep Medicine, Chicago, IL, USA (2005). • Provides all useful data for diagnosis of narcolepsy.
16. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann. Neurol. 53, 154-166 (2003). (Pubitemid 36163996)
17. Nobili L, Ferrillo F, Besset A, Rosadini G, Schiavi G, Billiard M. Ultradian aspects of sleep in narcolepsy. Neurophysiol. Clin. 26, 51-59 (1996). (Pubitemid 26162086)
18. Roehrs T, Zorick F, Wittig R, Paxton C, Sicklesteel J, Roth T. Alerting effects of naps in patients with narcolepsy. Sleep 9, 194-199 (1986). (Pubitemid 18008495)
19. Broughton R, Dunham W, Newman J, Lutley K, Dushesne P, Rivers M. Ambulatory 24 h sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr. Clin. Neurophysiol. 70, 473-481 (1988). (Pubitemid 18276074)
20. Nobili L, Besset A, Ferrillo F, Rosadini G, Schiavi G, Billiard M. Dynamics of slow wave activity in narcoleptic patients under bed rest conditions. Electroencephalogr. Clin. Neurophysiol. 95(6), 414-425 (1995). (Pubitemid 26020890)
21. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6), 540-545 (1991).
22. Littner MR, Kushida C, Wise M et al. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28(1), 113-121 (2005). • Provides a clear description of the correct way to use multiple sleep latency test and maintenance of wakefulness test.
23. Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 20, 43-50 (2006). (Pubitemid 43061721)
24. Overeem S, Reijntjes R, Huyser W, Lammers GJ, van Dijk JG. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J. Sleep Res. 13, 257-264 (2004). (Pubitemid 39331186)
25. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med. Rev. 8, 355-366 (2004). •• Comprehensive review on the pathophysiology and therapeutic management of cataplexy. (Pubitemid 39164485)
26. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J. Clin. Neurophysiol. 18, 78-105 (2001). (Pubitemid 32549906)
27. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Neurol. 67, 245-271 (1995).
28. Dahlitz M, Parkes JD. Sleep paralysis. Lancet 341, 406-407 (1993). (Pubitemid 23048146)
29. Montplaisir J, Billiard M, Takahashi S, Bell IR, Guilleminault C, Dement WC. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol. Psychiatry 13(1), 73-89 (1978). (Pubitemid 8285220)
30. Harsh J, Peszka J, Hartwig G, Mitler M. Night-time sleep and daytime sleepiness in narcolepsy. J. Sleep Res. 9, 309-316 (2000).
31. Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann. Neurol. 32(1), 3-10 (1992).
32. Nightingale S, Orgill JC, Ebrahim IO, de Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med. 6, 253-258 (2005). (Pubitemid 40613536)
33. Chokroverty S. Sleep apnea in narcolepsy. Sleep 9(1), 250-253 (1986). (Pubitemid 18008504)
34. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 355(9211), 1274-1275 (2000). (Pubitemid 30184546)
35. Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med. 5, 147-150 (2004). (Pubitemid 38351826)
36. Lammers GJ, Pijl H, Iestra J, Langius JAE, Buunk G, Meinders AE. Spontaneous food choice in narcolepsy. Sleep 19(1), 75-76 (1996). (Pubitemid 26049703)
37. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9(1), 254-259 (1986). (Pubitemid 18008505)
38. Vandeputte, M, de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med. 4, 343-345 (2003). (Pubitemid 36974815)
39. de Lecea L, Kildu TS, Peyron C et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322-327 (1998). (Pubitemid 28103952)
40. Sakurai T, Amemiya A, Ishii M et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998). (Pubitemid 28101119)
41. Lin L, Faraco J, Li R, Kadotani H et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98(3), 365-376 (1999). (Pubitemid 29380571)
42. Chemelli RM, Willie JT, Simon CM et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98(4), 437-451 (1999). (Pubitemid 29402482)
43. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev. 9, 231-241 (2005). (Pubitemid 40982495)
44. Peyron C, Tighe DK, van den Pol AN et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015 (1998). (Pubitemid 28543775)
45. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Neurol. 67, 245-271 (1995).
46. Siegel JM. REM Sleep. In: Principles and Practice of Sleep Medicine. Kryger MH, Roth T, Dement CD (Eds). Elsevier Saunders Editor, Philadelphia, PA, USA 120-135 (2005).
47. Wu MF, John J, Boehmer LN, Yao D, Nguyen GB, Siegel JM. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J. Physiol. 554(Pt 1), 202-215 (2004). (Pubitemid 38081453)
48. Simón-Arceo K, Ramírez-Salado I, Calvo JM. Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe. Sleep 26(3), 259-264 (2003). (Pubitemid 39610671)
49. McGinty D, Szymusiak R. Sleep-promoting mechanisms in mammals. In: Principles and Practice of Sleep Medicine. Kryger MH, Roth T, Dement CD (Eds). Elsevier Saunders, Philadelphia, PA, USA 169-184 (2005).
50. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 441 (7093), 589-594 (2006). (Pubitemid 43927285)
51. Ferrillo F, Donadio S, De Carli F, Garbarino S, Nobili L. A model-based approach to homeostatic and ultradian aspects of nocturnal sleep structure in narcolepsy. Sleep. 30(2), 157-165 (2007). (Pubitemid 46247841)
52. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med. Rev. 9, 269-310 (2005). (Pubitemid 40982498)
53. Billiard M, Bassetti C, Dauvilliers Y et al. EFNS guidelines on management of narcolepsy. Eur. J. Neurol. 13, 1035-1048 (2006). •• European guidelines for the management of narcolepsy and cataplexy. (Pubitemid 44434309)
54. Mignot E. An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy. Guest Editorial. Sleep Med. Rev. 8, 333-338 (2004). (Pubitemid 39164483)
55. Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep Med. Rev. 8, 339-354 (2004). •• Comprehensive review on the management of excessive daytime sleepiness. (Pubitemid 39164484)
56. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 27, 19-25 (2004). (Pubitemid 43906308)
57. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci. 20(22), 8620-8628 (2000).
58. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci. Lett. 339, 143-146 (2003). (Pubitemid 36254796)
59. Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Lambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance promoting drug modafinil. Neuropharmacology 39, 1974-1983 (2000). (Pubitemid 30645621)
60. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin. Pharmacokinet. 42(2), 123-137 (2003). (Pubitemid 36188553)
61. Billiard M, Besset A, Montplaisir J et al. Modafinil: a double-blind multicenter study. Sleep 17 (Suppl.), 107-112 (1994).
62. Broughton RJ, Fleming JAE, George CFP et al. Randomized, double-blind, placebo-controlled crossover of modafinil in rhe treatment of excessive daytime sleepiness in narcolepsy. Neurology 49, 444-451 (1997). (Pubitemid 27368880)
63. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann. Neurol. 43, 88-97 (1998).
64. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 54, 1166-1175 (2000).
65. Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin. Neuropharmacol. 26, 252-257 (2003). (Pubitemid 37221636)
66. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 1, 109-116 (2000).
67. Mitler MM, Hirsh J, Hirshkowitz M, Guilleminault C; for the US Modafinil in Narcolepsy Multicenter Study Group. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med. 1, 231-243 (2000).
68. Emsellem HA, Waskington DC and the US Modafinil Study Group. Efficacy and safety profiles of modafinil maintained during long-term (40 and 88 weeks) treatment of excessive daytime sleepiness associated with narcolepsy. Neurology 54(7 Suppl. 3), A29-A30 (2000).
69. Hirshkowitz M, Schwartz J, Corser B. Long-term (136 weeks) safety and efficacy of modafinil for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep 24(Suppl.), A329 (2001).
70. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 4(6), 579-582 (2003). (Pubitemid 38145661)
71. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep 17(4), 352-371 (1994).
72. Aldrich MS. Narcolepsy. N. Engl. J. Med. 323(6), 389-394 (1990).
73. Robinson DM, Keuting GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 21(4), 337-354 (2007). (Pubitemid 46598453)
74. US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled mulricenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25, 42-49 (2002).
75. US Xyrem Multicenter Study Group. A 12-month, open-label multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26, 31-35 (2003).
76. Mamelak M, Black J, Montplasir J. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27, 1327-1334 (2004). (Pubitemid 44138899)
77. The Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J. Clin. Sleep Med. 1, 391-397 (2005).
78. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29, 939-946 (2006).
79. Stahl S. Essential Psychopharmacology (1st Edition). Cambridge University Press, Cambridge, UK (2005).
80. Hublin C, Partinen M, Heinonen E, Puuka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 44, 2095-2101 (1994). (Pubitemid 24349511)
81. Mayer G, Meier-Ewert K. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin. Neuropharmacol. 18, 306-319 (1995).
82. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF; American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 30(12), 1712-1727 (2007). •• American Academy of Sleep Medicine recommendations for the management of excessive daytime sleepiness.
83. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 16, 444-456 (1993). (Pubitemid 23241668)
84. Potter W, Manji HK, Rudorfer MV. Triciclici e tetraciclici. In: The American Psychiatric Press Textbook of Psychopharmacology (2nd Edition). Schatzberg AF, Nemeroff CB (Eds). Italian Edition, Centro Scientifico Editore, Italy 199-218 (2001).
85. Tollefson GD, Rosenbaum JF. Inibitori selettivi della ricaptazione della serotonina. In: The American Psychiatric Press Textbook of Psychopharmacology (Second Edition). Schatzberg AF, Nemeroff CB (Eds). Italian Edition, Centro Scientifico Editore, Italy 219-237 (2001).
86. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr. Dis. Treat. 4(3), 557-566 (2008). •• Comprehensive review on the management of narcolepsy. (Pubitemid 352037835)
87. Hecht M, Lin L, Kushida CA et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin- deficiency narcolepsy. Sleep 26(7), 809-810 (2003). (Pubitemid 39610624)
88. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann. Neurol. 58(3), 489-490 (2005). (Pubitemid 41266641)
89. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J. Sleep Res. 12(4), 347-348 (2003). (Pubitemid 38010443)
90. Dauvilliers Y, Carlander B, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann. Neurol. 56, 905-908 (2004). (Pubitemid 39578460)
91. Zuberi SM, Mignot E, Ling L, Mcarthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J. Sleep Res. 13(Suppl. 1), 828 (2004).
92. Plazzi G, Poli F, Franceschini C et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J. Neurol. 255(10), 1549-1554 (2008).
93. Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J. Neurol. 255(12), 1900-1903 (2008).
94. Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc.) 44(6), 395-414 (2008).
95. Lankford DA. Armodafinil: a new treatment for excessive sleepiness. Expert Opin. Investig. Drugs 17(4), 565-573 (2008). (Pubitemid 351578173)
96. Summary of product characteristics. Modafinil. Patent no.: 5618845 Dompè S.p.A. March (2007).